In small cell lung cancer, there is sometimes a very old patient with comorbidity, and we were a little bit aware of the the toxicity of the molecule lurbinectedin, which is a very meaningful molecule with good objective response rate in small-cell lung cancer as second line treatment. So with our work, we we have conclude that elderly patient can receive safely the lurbinectedin without increase of the toxicities...
In small cell lung cancer, there is sometimes a very old patient with comorbidity, and we were a little bit aware of the the toxicity of the molecule lurbinectedin, which is a very meaningful molecule with good objective response rate in small-cell lung cancer as second line treatment. So with our work, we we have conclude that elderly patient can receive safely the lurbinectedin without increase of the toxicities. So that’s a good point because it’s a good molecule and we don’t want the elderly patient to be undertreated.